Anti-cancer activity of plant-produced HPV16 E7 vaccine

被引：79

作者：

Massa, Silvia ^{[1
]}

Franconi, Rosella ^{[1
]}

Brandi, Rossella ^{[1
]}

Muller, Antonio ^{[1
]}

Mett, Vadim ^{[1
]}

Yusibov, Vidadi ^{[1
]}

Venuti, Aldo ^{[1
]}

机构：

[1] BAS BIOTEC GEN, ENEA, Italian Natl Agcy New Technol, Energy & Environm, I-00123 Rome, Italy

来源：

VACCINE | 2007年 / 25卷 / 16期

关键词：

human papilloma virus; cancer vaccine; plant-produced vaccine;

D O I：

10.1016/j.vaccine.2007.01.018

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to beta-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：3018 / 3021

页数：4

共 14 条

[1]

Billington CK, 2003, RESP RES, V4

[2] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].

BOSCH, FX ;

MANOS, MM ;

MUNOZ, N ;

SHERMAN, M ;

JANSEN, AM ;

PETO, J ;

SCHIFFMAN, MH ;

MORENO, V ;

KURMAN, R ;

SHAH, KV ;

ALIHONOU, E ;

BAYO, S ;

MOKHTAR, HC ;

CHICAREON, S ;

DAUDT, A ;

DELOSRIOS, E ;

GHADIRIAN, P ;

KITINYA, JN ;

KOULIBALY, M ;

NGELANGEL, C ;

TINTORE, LMP ;

RIOSDALENZ, JL ;

SARJADI ;

SCHNEIDER, A ;

TAFUR, L ;

TEYSSIE, AR ;

ROLON, PA ;

TORROELLA, M ;

TAPIA, AV ;

WABINGA, HR ;

ZATONSKI, W ;

SYLLA, B ;

VIZCAINO, P ;

MAGNIN, D ;

KALDOR, J ;

GREER, C ;

WHEELER, C .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802

[3] Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation [J].

Fehrmann, F ;

Laimins, LA .

ONCOGENE, 2003, 22 (33) :5201-5207

[4]

Franconi R, 2002, CANCER RES, V62, P3654

[5] Prevention of cervical cancer through papillomavirus vaccination [J].

Frazer, IH .

NATURE REVIEWS IMMUNOLOGY, 2004, 4 (01) :46-54

[6] Therapeutic potential of protein and adjuvant vaccinations on tumour growth [J].

Gérard, CM ;

Baudson, N ;

Kraemer, K ;

Bruck, C ;

Garçon, N ;

Paterson, Y ;

Pan, ZK ;

Pardoll, D .

VACCINE, 2001, 19 (17-19) :2583-2589

[7] A controlled trial of a human papillomavirus type 16 vaccine [J].

Koutsky, LA ;

Ault, KA ;

Wheeler, CM ;

Brown, DR ;

Barr, E ;

Alvarez, FB ;

Chiacchierini, LM ;

Jansen, KU .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (21) :1645-1651

[8]

Lin KY, 1996, CANCER RES, V56, P21

[9]

MUSIYCHUK K, IN PRESS INFLUENZA O

[10]

Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt

← 1 2 →